As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
The goal of “Forever Welcome” is to help ensure that the United States is a safe place for immigrants to pursue their dreams.
Marketers continue to leverage the power of mobile devices, but have learned it’s not all about the apps.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Although patent expirations continue to depress revenue, AstraZeneca executives believe in the pipeline.
For Bayer, the acquisition of Monsanto is intended to build its Crop Science division; meanwhile two significant approvals and two new hires enhance progress in oncology.
Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.
Pfizer is overcoming patent expirations by developing a steady new stream of products.
Sanofi executives continue to have faith in strategic plans to get the company to new heights despite continued impact from patent expirations.
Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.
Healthcare communications agency Calcium hired Damon Tutulic as senior VP, management director.
Jacob Licht has become chief operating officer of VLP Therapeutics. Licht joined VLP Therapeutics after 10 years at Emergent BioSolutions, where he most recently served as VP, Corporate Development.
Jeffrey A. Meckler was appointed CEO of Intec Pharma Ltd. Meckler was named vice chairman of the Intec Pharma board of directors in April 2017 and continues in that role.
Greg Flynn was tapped as regional president of Ashfield Commercial and Clinical businesses in the United States. Flynn transitioned to this role from his position as regional president in Japan and representative director of CMIC Ashfield.
Manufacturers and their communications agencies see great opportunities in a new draft guidance from FDA, but the fear of warning letters still shadows the industry.
Scout, a specialty pharmaceutical advertising agency, has been acquired by a private equity fund. The agency was picked up by Stagwell Media LLC, the fund of the Stagewell Group.
For many of the healthcare advertising agencies featured within this annual special report, 2016 was another year of growth and change. With the election of Donald Trump as president of the United States and the United Kingdom’s Brexit vote to exit the European Union, the year also introduced uncertainty to agencies and their clients.
Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company’s Largest Investment in the United States
Advanced R&D, Manufacturing, and Packaging Facility to Serve as U.S. Headquarters; Initially Expected to Create Minimum of 150 Full-Time Jobs BROWARD COUNTY, Fla., March 8, 2017 /PRNewswire/ — Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan, including the development of a new R&D center […]
DynPort’s clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation FALLS CHURCH, Va., March 8, 2017 /PRNewswire/ — CSRA Inc. (NYSE: CSRA) today announced that a plague vaccine being developed by its subsidiary, DynPort Vaccine Company LLC (DVC), was granted Orphan Drug Designation from the U.S. Food and Drug Administration […]